News & Updates
Filter by Specialty:
Sex-specific prediction models help estimate pancreatic ductal adenocarcinoma risk in diabetes
The risk of pancreatic ductal adenocarcinoma (PDAC) appears to be higher among individuals with diabetes than in the general population, as well as in men than women, according to a study. Prediction models built around this finding demonstrate moderate accuracy for pinpointing men at high risk of PDAC, in whom surveillance may be required.
Sex-specific prediction models help estimate pancreatic ductal adenocarcinoma risk in diabetes
18 Jan 2022
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
15 Jan 2022
Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL
The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.
